AcyclovirThird Party Manufacturing in India

Acyclovir works by selectively inhibiting viral DNA replication in cells infected with herpesviruses. The drug itself is a pharmacologically inactive prodrug that requires intracellular phosphorylation to become active. This process begins when viral thymidine kinase, an enzyme specific to herpes simplex and varicella-zoster viruses, converts acyclovir into acyclovir monophosphate. Host cellular kinases then sequentially phosphorylate this intermediate into its active form, acyclovir triphosphate. Acyclovir triphosphate competitively inhibits viral DNA polymerase by mimicking the natural nucleotide deoxyguanosine triphosphate (dGTP). Once incorporated into the growing viral DNA strand, it acts as an obligate chain terminator because it lacks the 3'-hydroxyl group necessary for the attachment of subsequent nucleotides. This halts the elongation of the viral DNA chain and prevents viral replication. The selectivity of acyclovir ensures that it preferentially targets infected cells while sparing healthy host cells, which possess very low levels of the activating viral enzyme.

Therapeutic Uses

Acyclovir is a widely prescribed antiviral agent indicated for the treatment of infections caused by herpesviruses:

• Herpes Simplex Virus (HSV) Infections: Used in the management of genital herpes (primary and recurrent episodes), herpes simplex labialis (cold sores), and mucocutaneous HSV infections in immunocompromised patients.
• Varicella-Zoster Virus (VZV) Infections: Indicated for the treatment of herpes zoster (shingles) to reduce pain and duration, as well as varicella (chickenpox) in pediatric and adult patients.
• Herpes Simplex Encephalitis: Administered intravenously as a life-saving treatment for severe central nervous system herpes infections.
• Prophylaxis in Immunocompromised Patients: Used to prevent HSV outbreaks in patients undergoing chemotherapy or organ transplantation.

Why Manufacturers Choose Acyclovir

Acyclovir is on the WHO Model List of Essential Medicines and remains one of the most high-demand antiviral molecules globally. While oral tablets and topical ointments are common, the injectable formulation (250mg and 500mg) is a critical product for hospitals and intensive care units treating severe, systemic, or neurological herpes infections.

Indian pharmaceutical manufacturers with WHO-GMP certified sterile liquid and lyophilized injection lines have a strong market advantage. The global demand for acyclovir injections is driven by institutional hospital tenders, emergency care requirements, and private healthcare networks. Producing acyclovir injections requires strict compliance with aseptic processing standards, making it a high-value category with excellent margins for third-party manufacturing partners and exporters.

This makes Acyclovir one of the most sought-after antiviral molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.